Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move: TSX: $APH.TO,
TSXV: $EMC.V , TSXV: $LVWL.V , CSE: $KBEV.C , TSXV: $TBP.V
July 26th Potcast
sponsored by Lexaria Bioscience Corp. ( CSE: $LXX.C ) (OTC: $LXRP)
Delta, Kelowna, BC –July 26, 2018 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast’ site, www.potcasts.ca release today’s edition of its podcast series,
Investorideas.com potcastsCM
- cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at http://www.investorideas.com/news/2018/cannabis/07262Potcasts-TSXV-APH-EMC-LVWL-CSE-KBEV-TBP.asp
Today’s podcast overview/transcript:
Good morning and welcome to another Investorideas.com potcast ; looking
at cannabis news, stocks to watch as well as insights from thought leaders and
experts.
Today’s potcast was sponsored by Kelowna based Lexaria Bioscience Corp trading on the CSE under symbol LXX and on
the OTC as LXRP. Lexaria has developed a new disruptive
drug delivery platform: DehydraTECH The Company’s patented technology changes
the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally:
1) Masks unwanted tastes – eliminates the need for sugar-filled edibles.
2) Reduces time of onset – effects are felt within 15-20 min vs. 60-120
min.
3) Avoids first-pass liver metabolism
4) Increases bio-absorption by 5-10X
The Company’s DehydraTECH™ technology is patent-protected for multiple
APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal
anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine and Fat soluble
vitamins.
Today’s podcast features news announcements from Aphria Inc. trading on the TSX as APH and US OTC as APHQF, Emblem
Corp. trading on the TSX-Venture as EMC, LIVEWELL CANADA INC. trading on the
TSX-Venture as LVWL, Koios Beverage Corp. trading on the CSE as KBEV and the
OTC as SNOVF and Tetra Bio-Pharma Inc.,
trading on the TSX-VENTURE as TBP and the OTCQB as TBPMF.
Aphria Inc.
today announced that it completed its largest international shipment of
cannabis oil to date to Australian medical life science company, Medlab
Clinical Limited ("Medlab").
The shipment is part of the previously announced agreement between Aphria and
Medlab in which Aphria produces and supplies high-yield cannabis extracts for
Medlab to be used in a human trial to test the management of intractable pain
in oncology patients – the first trial of its kind globally.
For the
purposes of the clinical trial, Aphria has provided a high-CBD cannabis oil and
a high-THC cannabis oil, both of which were designed specifically for Medlab.
Once at Medlab, the products are then combined with Medlab's patented medicine
delivery system, NanoCelle™. Medlab's clinical trial is posited to provide an
effective and efficacious pain therapy targeted to advanced cancer pain, that
rivals standard opioid use. The product formulation, manufacturing, and final
product validation have met the TGO93 standard set by the Australian
Therapeutic Goods Administration ("TGA") and permits have been
approved by Health Canada.
Emblem Corp.
announced today that it has signed a non-binding Letter of Intent (“LOI”) to
acquire all of the issued and outstanding securities in Natura Naturals Inc.
(“Natura”) that it does not already own for $25 million in cash, $12.5 million
in mortgage financing and 26,102,941 common shares of Emblem. Based on Emblem’s
45 day VWAP of $1.36, the implied transaction value is $76 million (inclusive
of Natura shares already owned by Emblem). On completion of the Transaction,
Emblem will further its aggressive approach to sales growth both domestically
and internationally backed by robust supply from the Natura greenhouse.
Based in
Leamington, Ontario, Natura operates a 662,000 sq ft licensed greenhouse that
is currently undergoing a phased conversion and retrofit that is expected to
bring up to 15,000 kg of annualized cannabis production online in 2018. Once
completed in 2019, the facility is expected to bring total annualized cannabis
production capacity to approximately 70,000 kg per year.
The entering
into of the LOI follows Emblem’s recently announced $3 million equity
investment in Natura and the entering into of a 3,000 kg per year supply
agreement.
LIVEWELL
CANADA INC. greeted favourably the interest of the Government of Québec in
participating in the financing of its world-class Research and Innovation
Centre in Litchfield, in Pontiac RCM, Québec.
The
Government of Québec, through the Ministère de l'Économie, de la Science et de
l'Innovation of Québec (MESI) and in collaboration with Investissement
Québec, recently sent the Company a letter of interest stating that it is open
to contributing up to 25% of the overall financing of the project, subject to
terms to be determined in the near future.
The
President of LiveWell Canada, Mr. David Rendimonti, expressed his great
satisfaction in this offer of collaboration from the Government of Québec.
"This is a great step in our quest to develop new therapeutic and medical
solutions thanks to a world-class Research and Innovation Centre on hemp and
cannabis," he said.
Koios
Beverage Corp. announced that the first flavour of its new and improved line of
functional cognitive enhancing beverages, Pear Guava, is now available for
purchase.
Customers in
both Canada and the United States can order the drink online from the company's
website https://www.mentaltitan.com/product/pear-guava/ It is also
available for purchase through Koios's large distribution network, which
includes retailers such as SportLife Distribution, Max Muscle, and soon-to-be
available through Amazon online.
The new
formula enhances Koios's proprietary blend of nootropics by adding super foods
such as Lion's Mane Mushroom, a powerful ingredient recognized for enhancing
brain function, which Whole Foods recently listed as a trending ingredient in
its annual functional ingredients guide.
"We
have created the first drink of its kind," says CEO Chris Miller, who
founded the company in part because of his own personal experience with a
mental-health disorder, ADHD. The Global Brain Health market is expected
to grow by a CAGR of 20 per cent to $11.6 billion by 2024, and we are excited
to be innovating in the space and creating products that consumers are looking
for.
Koios
recently launched a wholly owned subsidiary, Cannavated Beverages Co. to
develop a line of cannabis infused, brain-healthy drinks for the legal
marijuana market.
Koios is
also one of the only drinks in the world to infuse its products with MCT
oil. MCT oil is derived from coconuts and has been shown to help the
body burn fat more effectively, create lasting energy from a natural food
source, produce ketones in the brain, allowing for greater brain function
and clarity, support healthy hormone production and improve immunity.
Tetra Bio-Pharma Inc., a leader
in cannabinoid-based drug discovery and development today announced that it
received two meeting granted letters from the United States Food and Drug
Administration (FDA), for Type B and C meetings, to discuss requirements for
obtaining marketing approval under the 505(b)(2) regulatory pathway for its
dronabinol AdVersa™ mucoadhesive product, PPP002.
Tetra, along
with its partner IntelGenx Corp, is developing this product in the USA under
the accelerated 505(b)(2) pathway for chemotherapy-induced nausea and vomiting
and anorexia and weight loss in people with AIDS (the same indications that
have already been approved for Marinol®). The 505(b)(2) speciality
Contract Research Organization, Camargo, is guiding the regulatory submissions
to the FDA. The corporation is also developing PPP002 in Canada as an adjunct
therapy for opioid reduction in patients with chronic pain.
Investor ideas reminds
all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Lexaria Bioscience Corp. has developed and
out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria's technology
provides increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Spotify, Google Play Music,
Stitcher iHeartradio and Tunein.
Potcasts is now a certified word
mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires
Big Ideas
Investorideas.com is
a meeting place for global investors, featuring news, stock directories, video,
company profiles, interviews and more in leading sectors.
Investorideas.com
cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the
Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com
, the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria
Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast
starting July 5 2018 more info
http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with Sedar.
Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Do you trade or invest in Marijuana / Hemp
Stocks? Check out our stock directory of
publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX
Marijuana / Hemp Stocks
Join our Group on Linkedin and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing
No comments:
Post a Comment